Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 26

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 26
---
 as of the Record Date.

| Example Ratios within Delegated Range of Ratios |     |       Implied 
   Approximate 
     Number of 
    Issued and 
   Outstanding 
     Shares of 
  Common Stock 
 Following the 
 Reverse Stock 
      Split(1) |
| 1-for-2                                         |     |     2,584,862 |
| 1-for-10                                        |     |       516,972 |
| 1-for-15                                        |     |       344,648 |
| 1-for-20                                        |     |       258,486 |
| 1-for-25                                        |     |       206,789 |

____________ (1)Excludes the effect of fractional share treatment. We are exploring various sources of financing, including through potential future sales of Common Stock or other securities. There can be no assurance, however, even if the Reverse Stock Split is approved and implemented, that any financing transaction would be undertaken or completed. If we are unable to successfully raise sufficient additional capital, through future sales of Common Stock or other securities or through strategic and collaborative arrangements, we will not have sufficient cash to fund our planned business operations and or may not be able to continue as a going concern.

11 As of the Record Date, we had 5,169,723shares of Common Stock issued and outstanding, 471,199shares of Common Stock reserved for issuance upon the exercise of outstanding options, 3,405,498shares of Common Stock reserved for issuance upon the exercise of outstanding Warrants (as defined below), and 0shares of Common Stock reserved for future issuances under the 2024 Plan. As of the Record Date, we had 1,429shares of Series A convertible preferred stock, par value $0.0001 per share (the “Series A Preferred Stock”), 198shares of Series B convertible preferred stock, par value $0.0001 per share (the “Series B Preferred Stock”), and 2,537shares of Series C convertible preferred stock, par value $0.0001 per share (the “Series C Preferred Stock”) issued and outstanding. Based upon a conversion price of $1.96, the shares of Series A Preferred Stock are convertible into 729,082shares of Common Stock, the shares of Series B Preferred Stock are currently convertible at the Alternate Conversion Price (as defined below), and based upon a conversion price of $1.96, the shares of Series C Preferred Stock are convertible into